Longevity Medicine, Memberships and the Evidence | CMT Research Brief No. 31
Educational content only. Not medical, legal, tax, financial or accounting advice. Read the disclaimer.
Concierge Medicine TodayCMT Research Brief No. 31 · Evidence and Business Models · November 2026
Research Brief No. 31Evidence and Business ModelsPrimary evidence: Practice Insight

Longevity Medicine, Memberships and the Evidence

Longevity care is sold through concierge memberships, standalone clinics, subscriptions and cash-only tests. How the models differ, what they cost, and what the evidence behind common services actually shows.

Updated November 2026: replaced and expanded at the editor's request; adds business models, pricing, HSA rules and a concierge vs longevity clinic comparison to the original evidence framework; evidence labels follow CMT's five evidence types.

$7,500 to $15,000
Biograph first-year membership tiers
142,000
people in the randomized NHS-Galleri trial; primary endpoint not met
$150 / $300
2026 monthly HSA cap for qualifying DPC (individual / family)

Start here: the questions this brief answers

The 30-second answer

Longevity care comes as concierge memberships, standalone clinic memberships, subscriptions, cash-only tests and executive physicals, at very different prices. The evidence varies by service: one-time Lp(a) testing and fitness are well supported; whole-body MRI and multi-cancer blood tests are not proven to improve outcomes. The physician relationship is what turns test results into care.

How is longevity care sold?

Five models, from concierge memberships to cash-only tests. Go to the full answer ↓

What do longevity memberships cost?

Biograph lists $7,500 and $15,000 first-year tiers; contemporary concierge is mostly $100 to $750 a month (CMT estimate). Go to the full answer ↓

Can patients use an HSA?

Qualifying DPC up to $150 a month (individual) since 2026; most concierge and longevity memberships don't qualify. Go to the full answer ↓

Are full-body MRIs worth it?

The ACR says evidence is insufficient to recommend them for people without symptoms. Go to the full answer ↓

What's the difference between concierge and a longevity clinic?

A continuing relationship versus concentrated testing. Go to the full answer ↓

Written for: Concierge physiciansPractice owners adding servicesPatients comparing membershipsJournalists

Part 1 · Why this brief

Longevity is now a business model. Patients need a way to judge it.

Longevity medicine sells the promise of more healthy years. It is sold through concierge memberships, standalone longevity clinics, subscriptions and cash-only tests. The evidence behind each service varies widely.

Version 1.0 of this brief introduced an evidence framework for longevity tests and treatments. Version 2.0 keeps that framework and adds the business side: how longevity care is packaged and priced, how it compares with concierge medicine, and what physicians should ask before adding a longevity service.

CMT's editorial position

Longevity care is not the problem. Selling uncertain tests as certainty is. A membership earns trust when it tells patients what each service can and cannot do, and when the physician relationship, not the scanner, is the product.

Part 2 · The business models

Five ways longevity care is sold

ModelHow patients payWhat it usually includesExample price in the public recordEvidence type
Concierge membership with a longevity focusRecurring fee, often plus insurance billingOngoing physician relationship, access, prevention planningContemporary concierge is mostly about $100 to $750 a month (CMT field estimate)1Industry Research
Standalone longevity clinic membershipAnnual fee, self-payIntensive testing day (imaging, labs, fitness), coachingBiograph: $7,500 (Core) or $15,000 (Black), first year2; Fountain Life: about $6,500 to $21,500 a year, as described by the company3Industry Research
Cash-only, à la carte testsPer test, self-paySingle scans or blood panels without a continuing relationshipVaries widely; prices change oftenIndustry Research
Subscription telehealth programsMonthly subscriptionRemote visits, labs, sometimes prescriptionsVaries; CMT has no verified benchmarkIndustry Research
Hospital executive healthPer visit, patient or employerOne- or two-day evaluationSee Brief No. 07Industry Research

Direct primary care · a different model · HSA rules

Since January 1, 2026, qualifying direct primary care arrangements no longer disqualify a patient from HSA contributions, and HSA funds can pay the fee, if the arrangement provides only primary care for a fixed periodic fee of no more than $150 a month for an individual or $300 for a family in 2026.4 Concierge and longevity memberships that bill insurance, exceed the cap or include specialty services generally fall outside this rule. Patients should check with a tax professional.

These rules describe DPC, not concierge medicine, and are shown separately for context only. Not tax advice.

Example annual price points for longevity and concierge offerings

Industry Research
Biograph Black membership, first year$15,000
Biograph Core membership, first year$7,500
Contemporary concierge, upper end (about $750 a month)About $9,000
Contemporary concierge, lower end (about $100 a month)About $1,200

Sources: Biograph pricing page2; CMT field estimate for concierge tiers, method not published.1 Concierge figures are annualized ranges, not a specific practice. Prices change; confirm before publishing.

Part 3 · The evidence framework

What the evidence says about common longevity services

Each row shows the evidence type behind the finding and a separate verdict marked as CMT's editorial reading. Evidence types describe the kind of evidence, not its value. The CMT reading is a plain-language summary for clinicians, not a clinical recommendation for any patient.

ServiceEvidence typeWhat the evidence saysCMT editorial reading
Whole-body MRI screening (no symptoms)Practice InsightThe ACR found insufficient evidence to recommend total-body screening and no documented evidence it is cost-efficient or prolongs life.5 Radiology leaders warn of false positives and overdiagnosis as use grows.6Not a screening substitute. If offered, disclose uncertainty and the likelihood of incidental findings.
Multi-cancer blood test (Galleri)Clinical Trial EvidenceIn the randomized NHS-Galleri trial of about 142,000 people, the primary endpoint of reducing stage III to IV cancers was not met, though stage IV diagnoses fell.7 An FDA panel backed the test in 2026, but that is not approval; the panel urged continuing standard screening.8Promising but unproven for outcomes. Never replaces guideline screening.
Lipoprotein(a), measured oncePractice InsightThe National Lipid Association recommends measuring Lp(a) at least once in every adult; European and Canadian guidance agree.9Reasonable and inexpensive; acting on a high result means managing other risk factors more intensively.
Coronary artery calcium (CAC) scorePolicy and LawThe USPSTF found insufficient evidence to add CAC to routine risk assessment.10 Cardiology guidelines support CAC for intermediate-risk adults when it would change statin decisions.11Useful when the result would change treatment; not a universal screen.
Cardiorespiratory fitness (VO2 max or treadmill)Population DataAmong 122,007 patients, the lowest-fitness group had about five times the adjusted mortality of the most fit, a risk comparable to or greater than smoking or diabetes.12 Observational: fitness may also reflect other healthy traits.Strong signal and modifiable. Exercise prescription may matter more than the test.

Part 4 · Concierge vs longevity clinic

Relationship or testing day?

Concierge strength

A continuing relationship with a physician who knows the patient and can act on results over years. Studies of one large network link membership with fewer hospitalizations, though they are observational and network-affiliated.13 A 2025 systematic review examined cost, access and outcomes.14

Longevity clinic strength

Concentrated, convenient testing and coaching. Pricing is clear and published.2

Shared risk

Selling tests with uncertain benefit as certainty. Incidental findings can lead to anxiety, further tests and costs that the membership may not cover.5

Before adding a longevity service to your membership

0 complete

Nothing you check is saved or sent anywhere. Educational self-review only.

Learn → Build → Lead

Putting it to work

Learn

Longevity services range from well supported to unproven; label them honestly.

Build

Run the checklist before adding any test to a membership.

Lead

Make the physician relationship, not the scanner, the core of what you sell.

Methods, limitations and evidence types

How this brief was built

CMT rebuilt this brief at the editor's request, replacing Version 1.0. Each scorecard row shows the evidence type and, separately, a verdict marked as CMT's editorial reading. Company prices come from company pages and trade reports and are labeled Industry Research. DPC appears only in the dashed HSA box.

Every key finding is labeled by evidence type. Labels describe the type of evidence, not its value. Each type answers different questions. Funding is disclosed on every source.

Clinical Trial EvidenceRandomized trials and systematic reviewsBest for: Cause and effect
Population DataLarge observational studies and government dataBest for: Trends at scale
Practice InsightSurveys, smaller studies and expert consensusBest for: Real-world experience
Industry ResearchCompany-sponsored or company-reported data that is not peer-reviewedBest for: Early signals and operating data
Policy and LawStatutes, regulation and official guidanceBest for: What is required

What we don't know

  • No independent study compares outcomes of longevity clinic members with concierge members.
  • Longevity clinic prices change frequently and some are quote-based.
  • Final FDA action on multi-cancer blood tests was pending at publication.
  • CMT has no verified benchmark for subscription telehealth longevity programs.

How to cite this brief

Concierge Medicine Today. Longevity Medicine, Memberships and the Evidence. CMT Research Brief No. 31, Version 2.0. November 2026. conciergemedicinetoday.net/longevity-evidence-grades.

External review: This brief has not been externally peer reviewed. Corrections: CMT corrects factual errors promptly and notes the change in the updates line. Send corrections through conciergemedicinetoday.net/contact.

References

Sources and citations

  1. Concierge Medicine Today. Concierge price tier field estimates. CMT field estimate, method not published. conciergemedicinetoday.netEvidence type: Industry Research · Funding: Concierge Medicine Today (self-conducted; no outside funder)
  2. Biograph. Memberships page: Core $7,500 and Black $15,000, first year. Accessed November 2026. biograph.comEvidence type: Industry Research · Funding: not stated (company pricing page)
  3. AgeMed. Report on longevity clinic pricing; Fountain Life memberships from $6,500 to $21,500 a year as described by the company. agemed.orgEvidence type: Industry Research · Funding: not stated (trade article quoting company)
  4. Internal Revenue Service. Notice 2026-5, Expanded availability of health savings accounts under the One, Big, Beautiful Bill Act. December 2025. Fee limits as summarized by HUB International and Groom Law Group. irs.govEvidence type: Policy and Law · Funding: federal (IRS)
  5. American College of Radiology. ACR statement on screening total body MRI. April 17, 2023. Reaffirmed per ACR spokesperson, October 2024 (Radiology Today). acr.orgEvidence type: Practice Insight · Funding: not stated (professional society statement)
  6. RSNA News. Whole-body MRI expands, leaving patients weighing risks. July 2026. rsna.orgEvidence type: Practice Insight · Funding: not stated (society news report)
  7. Patient Care. NHS-Galleri data show fewer stage IV cancers, but primary endpoint missed. February 20, 2026. Randomized trial of about 142,000 participants. Summary via Patient Care, citing GRAIL. patientcareonline.comEvidence type: Clinical Trial Evidence · Funding: industry (GRAIL; trial run with NHS England), per company and trade reports
  8. Patient Worthy. Galleri moves closer to FDA decision as evidence on multi-cancer blood testing evolves. October 4, 2026. Summary via Becker's Hospital Review of the FDA advisory panel's nonbinding recommendation. patientworthy.comEvidence type: Policy and Law · Funding: not stated (news report)
  9. Koschinsky ML, Bajaj A, Boffa MB, et al. A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice. Journal of Clinical Lipidology. 2024. doi:10.1016/j.jacl.2024.03.001. pubmed.ncbi.nlm.nih.govEvidence type: Practice Insight · Funding: not stated (professional society statement; check article disclosures)
  10. U.S. Preventive Services Task Force. Risk assessment for cardiovascular disease with nontraditional risk factors (ABI, hsCRP, CAC). 2018 recommendation (I statement). Summary via The Hospitalist. the-hospitalist.orgEvidence type: Policy and Law · Funding: federal (AHRQ supports the USPSTF)
  11. 2018 AHA/ACC multisociety guideline on the management of blood cholesterol. CAC recommendation for intermediate-risk adults. Summary via AAFP, October 2, 2023. aafp.orgEvidence type: Practice Insight · Funding: not stated (guideline; check disclosures)
  12. Mandsager K, Harb S, Cremer P, Phelan D, Nissen SE, Jaber W. Association of cardiorespiratory fitness with long-term mortality among adults undergoing exercise treadmill testing. JAMA Network Open. 2018;1(6):e183605. 122,007 patients. healio.comEvidence type: Population Data · Funding: not stated; authors reported no relevant financial disclosures (per Healio)
  13. Klemes A, et al. Personalized preventive care leads to significant reductions in hospital utilization. American Journal of Managed Care. 2012;18(12):e453-e460. ajmc.comEvidence type: Population Data · Funding: not confirmed by CMT; authors included MDVIP medical leadership
  14. Rylands KS, Collins CM, Collins DR. Maximizing the value of concierge medicine: a systematic review of cost, access, and outcomes. American Journal of Medicine. 2025;138(9):1201-1213. doi.orgEvidence type: Clinical Trial Evidence · Funding: not stated (check article)

Disclaimer

This brief is educational and informational only. It is not medical, legal, tax, financial or accounting advice, and it is not media training or a substitute for advice from a qualified professional. Concierge Medicine Today is an independent trade publication: no organization paid for favorable coverage, no practice model is favored, and funding is disclosed for every source cited. Product, company and organization names are used for identification and context only and do not imply endorsement. While we work to be accurate, this content is not without possible error or omission. © 2007-2026 Concierge Medicine Today, LLC. All rights reserved.

See all Research Briefs Learn about the Concierge Medicine Forum

Concierge Medicine Today · independent trade publication since 2007 · Learn → Build → Lead